These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35075155)

  • 1. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
    Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
    Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.
    Cao Y; Dai Y; Zhang L; Wang D; Yu Q; Hu W; Wang X; Yu P; Ping Y; Sun T; Sang Y; Liu Z; Chen Y; Tao Z
    Clin Biochem; 2022 Feb; 100():35-41. PubMed ID: 34843732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
    West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
    Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
    Ezirike Ladipo J; He Z; Chikwava K; Robbins K; Beri J; Molle-Rios Z
    J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):352-357. PubMed ID: 34117193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
    Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
    Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
    Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
    EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
    Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
    Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
    Bank S; Julsgaard M; Abed OK; Burisch J; Broder Brodersen J; Pedersen NK; Gouliaev A; Ajan R; Nytoft Rasmussen D; Honore Grauslund C; Roug S; Galsgaard J; Sprogøe Høyer Finsen D; Lindby K; ; Sørensen J; Larsen L; Rohr Andersen M; Brandslund I; Thomassen M; Green A; Bo Bojesen A; Bek Sørensen S; Vogel U; Andersen V
    Aliment Pharmacol Ther; 2019 Apr; 49(7):890-903. PubMed ID: 30811631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
    Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
    Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
    Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab.
    Bertani L; Barberio B; Fornili M; Antonioli L; Zanzi F; Casadei C; Benvenuti L; Facchin S; D'Antongiovanni V; Lorenzon G; Ceccarelli L; Baglietto L; de Bortoli N; Bellini M; Costa F; Savarino EV; Fornai M
    Dig Liver Dis; 2022 Oct; 54(10):1367-1373. PubMed ID: 35393259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
    Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
    Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.